By Ben Hirschler
LONDON, June 10 (Reuters) - AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
The acquisition of the privately held company secures AstraZeneca a position in the emerging market for a new class of lung treatments known as LABA/LAMA drugs that promise improved patient compliance and disease control, without steroids.
http://www.reuters.com/article/2013/06/10/astrazeneca-pearl-idUSL5N0EM0FJ20130610?rpc=401
No comments:
Post a Comment